By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
While Intuitive Surgical (ISRG) has shown strong operational performance, the market has priced in much of its future growth. Competitive pressure from Medtronic's Hugo and potential commoditization of robotic surgery pose risks, along with macroeconomic factors such as hospital labor shortages and capital expenditure cycles.
Risk: Inevitable commoditization of robotic surgery and potential price war, as well as macroeconomic factors affecting hospital capital expenditure cycles.
Opportunity: Strong operational execution in a structurally attractive market, with aging populations and procedure volume recovery.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
With an upside potential of 35.5%, Intuitive Surgical, Inc. (NASDAQ:ISRG) remains a bullish pick among analysts. The stock, therefore, earns its place on our list of the best agentic AI stocks to buy right now.
On April 21, 2026, Intuitive Surgical, Inc. (NASDAQ:ISRG) reported strong first-quarter results, exceeding Wall Street projections in both revenue and earnings, owing to continued global demand for its da Vinci robotic surgery systems used in minimally invasive treatments.
As reported on ** Reuters**, Intuitive Surgical, Inc. (NASDAQ:ISRG) recorded revenue of $2.77 billion compared with the $2.62 billion forecast and adjusted EPS of $2.50, compared with $2.1 expected. Strong procedure momentum supported growth, with da Vinci procedures increasing by about 16% year-over-year as hospitals continued to reduce surgical backlogs and expand the use of robotic-assisted care across a wider range of procedures.
Despite a projected 1% tariff-related headwind, management raised its gross margin target to 67.5%-68.5% and increased its full-year outlook, now predicting 2026 da Vinci procedure growth of 13.5%-15.5%, slightly above previous guidance. The results strengthened Intuitive Surgical, Inc. (NASDAQ:ISRG)’s position as the industry leader in robotic-assisted surgery, despite growing competition following FDA approval of Medtronic’s Hugo, a Robotically Assisted Surgery (RAS) system.
On April 22, 2026, Piper Sandler reiterated its “Overweight” rating but lowered its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) from $620 to $580, citing broad compression in valuation multiples rather than a decline in fundamentals.
The results demonstrated ongoing execution strength, with an adjusted gross margin of 67.8%, higher than anticipated. That reflects the company’s steady procedure-driven growth and robust profitability.
Intuitive Surgical, Inc. (NASDAQ:ISRG) engages in the development, manufacturing, and marketing of da Vinci surgical systems and the Ion endoluminal system.
While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"Intuitive Surgical's valuation is currently stretched to a point where the 'AI' narrative is doing more heavy lifting than the actual clinical growth trajectory."
ISRG is a classic 'quality compounder' masquerading as an AI play. While the article leverages the 'agentic AI' buzzword to drive interest, the real story is the 16% procedure growth and the recurring revenue model from the Ion and da Vinci ecosystems. At current valuations—trading at a forward P/E north of 50x—the market has already priced in perfection. The margin expansion to 68% is impressive, but the real risk isn't just valuation compression; it is the inevitable commoditization of robotic surgery as Medtronic’s Hugo and JNJ’s Ottava gain clinical traction, which will eventually force a price war that current analyst models are largely ignoring.
The bull case relies on ISRG's massive installed base creating a 'moat' so deep that even significant competition cannot erode their market share or pricing power for years.
"N/A"
[Unavailable]
"ISRG's fundamentals are strong but already reflected in price; the real risk is that procedure growth moderates below 13.5% or Hugo captures faster-than-expected share, both of which would trigger multiple compression beyond what's already priced."
ISRG beat Q1 badly (revenue +5.7% vs. forecast, EPS +19% vs. forecast), raised FY26 guidance to 13.5%-15.5% procedure growth, and posted 67.8% gross margin—all genuine operational wins. But the article's 35.5% upside claim is unmoored: Piper Sandler *lowered* price target from $620 to $580 same day, explicitly citing valuation compression despite strong fundamentals. That's the real story. ISRG is executing flawlessly in a structurally attractive market (aging populations, procedure volume recovery), but the stock has already priced in much of that. The 'agentic AI' framing is marketing—da Vinci isn't an autonomous agent; it's tele-operated robotics with some autonomy features. Medtronic's Hugo approval is real competitive pressure, not yet quantified in lost share.
If procedure growth sustains at 14-15% with margin expansion to 68%+, and if ISRG's installed base and switching costs create a durable moat against Hugo, then current valuation could be justified and multiples could re-rate upward—especially if the market rotates back into high-quality, low-volatility growth names.
"Durable top-line growth for ISRG depends on steady procedure volumes and margin retention, but the valuation risk remains if AI hype wanes and competitive pressure intensifies."
ISRG's Q1 beat highlights strong demand for da Vinci and a lift in gross margin, supporting a higher full-year guide and a 13.5–15.5% da Vinci procedure growth. Yet labeling ISRG as an 'agentic AI stock' risks conflating surgical robotics with AI hype. The upside already looks priced in given potential multiple compression, and competitive pressure from Hugo—plus potential reimbursement and capital-expenditure headwinds—could erode margins or cap procedure growth. If backlogs unwind or hospital budgets tighten, earnings catalysts may thin. Regulatory risk and onshoring dynamics add unknowns, while the Ion system remains a smaller growth driver. Valuation hinges on AI adoption confidence, not just execution.
The AI framing may overstate the driver; ISRG’s cash flow rests on ongoing procedure volumes and service revenue, not AI breakthroughs. If healthcare capex slows or Hugo penetrates more deeply, the stock could underperform despite solid execution.
"Hospital capex sensitivity to interest rates poses a greater threat to ISRG's growth than Medtronic or JNJ competition."
Gemini and Claude focus on competition, but you’re all missing the real macro risk: hospital labor shortages and capital expenditure cycles. ISRG’s success is tethered to hospital profitability. If interest rates remain 'higher for longer,' hospital CFOs will delay the massive upfront capex required for new da Vinci systems. Even with a recurring revenue model, a slowdown in new system placements will eventually cannibalize future procedure growth. The moat isn't just competition; it's the hospital balance sheet.
[Unavailable]
"Labor shortages drive procedure demand, but capex cycles drive system placements—conflating them obscures which margin actually compresses first."
Gemini's capex cycle risk is real, but the framing conflates two separate pressures. Hospital labor shortages *increase* demand for robotics—they're a tailwind, not headwind. The actual risk is capex timing: if rates stay elevated, hospitals defer new system purchases, compressing placements. But ISRG's installed base generates recurring revenue (consumables, service) that's less sensitive to new capex cycles. The moat question isn't whether competition erodes it—it's whether recurring revenue can sustain growth if placement growth stalls. That's underexplored.
"Overlooked risk: margin/ growth dynamics if placements slow; consumables and service must offset slower new unit demand; AI framing fades; upside hinges on durable maintenance/ Ion demand."
Gemini's macro capex warning is valid, but the bigger overlooked risk is margin/growth dynamics if system placements slow. Even with a robust installed base, consumables and service revenue must compensate for slower new unit demand; any blunt capex pause or delay could compress gross margins from 67–68% toward low-60s, pressuring multiples. The AI framing may fade; real upside hinges on durable demand for maintenance and Ion, not just da Vinci growth.
While Intuitive Surgical (ISRG) has shown strong operational performance, the market has priced in much of its future growth. Competitive pressure from Medtronic's Hugo and potential commoditization of robotic surgery pose risks, along with macroeconomic factors such as hospital labor shortages and capital expenditure cycles.
Strong operational execution in a structurally attractive market, with aging populations and procedure volume recovery.
Inevitable commoditization of robotic surgery and potential price war, as well as macroeconomic factors affecting hospital capital expenditure cycles.